CN115124628A - 一种白及多糖及其制备方法和应用、包含所述白及多糖的免疫佐剂和纳米疫苗 - Google Patents
一种白及多糖及其制备方法和应用、包含所述白及多糖的免疫佐剂和纳米疫苗 Download PDFInfo
- Publication number
- CN115124628A CN115124628A CN202110328789.3A CN202110328789A CN115124628A CN 115124628 A CN115124628 A CN 115124628A CN 202110328789 A CN202110328789 A CN 202110328789A CN 115124628 A CN115124628 A CN 115124628A
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- bletilla striata
- vaccine
- striata polysaccharide
- bletilla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 90
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 90
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 90
- 241001313857 Bletilla striata Species 0.000 title claims abstract description 61
- 229960005486 vaccine Drugs 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000000568 immunological adjuvant Substances 0.000 title claims abstract description 7
- 241001313855 Bletilla Species 0.000 claims abstract description 24
- 229940023143 protein vaccine Drugs 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 46
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 27
- 238000002156 mixing Methods 0.000 claims description 24
- 239000007864 aqueous solution Substances 0.000 claims description 23
- 239000000047 product Substances 0.000 claims description 18
- 239000002244 precipitate Substances 0.000 claims description 17
- 239000011780 sodium chloride Substances 0.000 claims description 16
- 230000002519 immonomodulatory effect Effects 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 238000004440 column chromatography Methods 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 claims description 9
- 238000005238 degreasing Methods 0.000 claims description 9
- 238000010828 elution Methods 0.000 claims description 9
- 238000000105 evaporative light scattering detection Methods 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 239000011259 mixed solution Substances 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- 239000002131 composite material Substances 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 229940031937 polysaccharide vaccine Drugs 0.000 claims description 2
- 230000001571 immunoadjuvant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000010355 oscillation Effects 0.000 claims 1
- 230000007365 immunoregulation Effects 0.000 abstract description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract description 6
- 239000002245 particle Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 238000001338 self-assembly Methods 0.000 abstract description 3
- 230000005875 antibody response Effects 0.000 abstract description 2
- 239000000427 antigen Substances 0.000 abstract description 2
- 102000036639 antigens Human genes 0.000 abstract description 2
- 108091007433 antigens Proteins 0.000 abstract description 2
- 230000036755 cellular response Effects 0.000 abstract description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000002386 leaching Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 229920002271 DEAE-Sepharose Polymers 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000012506 Sephacryl® Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- VPWNQTHUCYMVMZ-UHFFFAOYSA-N 4,4'-sulfonyldiphenol Chemical compound C1=CC(O)=CC=C1S(=O)(=O)C1=CC=C(O)C=C1 VPWNQTHUCYMVMZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- -1 aprotic carbon Chemical compound 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 230000003544 deproteinization Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000012844 infrared spectroscopy analysis Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000010829 isocratic elution Methods 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 150000002987 phenanthrenes Chemical class 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920000869 Homopolysaccharide Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 241001112090 Pseudovirus Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Materials Engineering (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Pulmonology (AREA)
- Sustainable Development (AREA)
- Alternative & Traditional Medicine (AREA)
Abstract
本发明提供了一种白及多糖及其制备方法和应用、包含所述白及多糖的免疫佐剂和纳米疫苗,属于免疫调节技术领域。本发明的白及多糖具有免疫调节作用,本发明的白及多糖和蛋白疫苗混合后,会发生自组装现象生成纳米疫苗,自组装后的纳米疫苗为较为均一的圆形颗粒。利用纳米疫苗免疫小鼠时,其能够通过激活抗原呈递细胞(APCs)并提高其对抗原的摄取,该纳米疫苗产生了比传统疫苗强2~10倍的抗体和细胞应答。
Description
技术领域
本发明涉及免疫调节技术领域,尤其涉及一种白及多糖及其制备方法和应用、包含所述白及多糖的免疫佐剂和纳米疫苗。
背景技术
中药白及为兰科(Orhidaceae)植物白及属(Bletilla)白及Bletilla striata(Thunb.)Reichb.f.的干燥块茎,具有收敛止血,消肿生肌,补肺止咳的功效。目前文献报道的白及属的主要化学成分为联苄(bibenzyls)、菲类(phenanthrenes)及其衍生物、甾体皂苷、三萜、黄酮、花青素等,共150余种。这些成分在后续的研究中表现出多样的生物活性,如抗炎、抗氧化,抗菌、止血、抗肿瘤和抑制络氨酸酶等。
白及富含多糖,目前报道的白及多糖骨架类型主要为1,2-或1,4-链接甘露糖残基与葡萄糖残基1,4-链接方式,传统白及多糖的制备与应用多集中在伤口愈合方面,或者作为加工代血浆、血管栓塞剂用于肿瘤的介入治疗。
发明内容
本发明的目的在于提供一种白及多糖及其制备方法和应用、包含所述白及多糖的免疫佐剂和纳米疫苗,本发明提供的白及多糖具有免疫调节作用。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了一种白及多糖,化学结构式如式I所示;所述白及多糖的相对分子量为42.0~42.5KDa;
优选的,所述白及多糖的相对分子量为42.4KDa。
本发明还提供了上述方案所述白及多糖的制备方法,包括以下步骤:
1)对白及块茎粉进行脱脂处理,得到脱脂原料;
2)将所述脱脂原料和水混合进行水提,得到水提液;
3)采用乙醇对所述水提液进行醇沉,固液分离,收集沉淀;
4)对所述沉淀进行脱蛋白处理,得到白及粗多糖;
5)依次采用水和浓度为0.05mol/L的NaCl水溶液对所述白及粗多糖进行第一色谱柱层析,收集NaCl水溶液的洗脱部分;采用水对NaCl水溶液的洗脱部分进行第二色谱柱层析,收集洗脱液,对所述洗脱液进行HPLC-ELSD 检测,收集出峰时间为9.32min的组分,得到白及多糖。
优选的,步骤3)中所述采用乙醇对所述水提液进行醇沉包括:对所述水提液依次进行过滤和浓缩,得到浓缩液;将所述浓缩液和乙醇混合,得到混合液,静置进行醇沉;所述混合液中乙醇的体积浓度>70%。
优选的,步骤4)中所述脱蛋白处理包括:对所述沉淀复溶,得到复溶液;将所述复溶液与Sevage试剂按照体积比为4:1的比例混合、振荡、离心,变性后的蛋白质介于复溶液与Sevage试剂交界处;所述Sevage试剂是将氯仿和正丁醇按照4:1的体积比混合得到。
本发明还提供了上述方案所述白及多糖或者上述方案所述制备方法制备得到的白及多糖在制备免疫调节产品中的应用。
优选的,所述免疫调节产品包括免疫调节药品、免疫调节化妆品或免疫调节功能食品。
本发明还提供了上述方案所述白及多糖或者上述方案所述制备方法制备得到的白及多糖作为免疫佐剂在制备疫苗中的应用。
本发明还提供了一种纳米疫苗,包括多糖和蛋白疫苗,所述多糖为上述方案所述白及多糖或者上述方案所述制备方法制备得到的白及多糖。
优选的,所述蛋白疫苗包括SARS-CoV-2RBD蛋白。
本发明提供了一种白及多糖。本发明的白及多糖具有免疫调节作用,本发明的白及多糖和蛋白疫苗混合后,会发生自组装现象生成纳米疫苗,自组装后的纳米疫苗为较为均一的圆形颗粒。利用纳米疫苗免疫小鼠时,其能够通过激活抗原呈递细胞(APCs)并提高其对抗原的摄取,该纳米疫苗产生了比传统疫苗强2~10倍的抗体和细胞应答。
附图说明
图1为实施例1中白及多糖提取的流程图;
图2为实施例1中白及多糖分离纯化的流程图;
图3为BPS纯品HPLC图谱;
图4为BPS纯品PMP-HPLC图谱;
图5为BPS纯品IR图谱;
图6为BPS纯品UV图谱;
图7表示BPS纯品中所有的氢质子信号;
图8表示BPS纯品中所有的氢原子信号;
图9表示BPS纯品中碳与其附着氢质子之间的关联性;
图10表示BPS纯品中氢质子与碳(包括非质子碳、远离质子的两个或三个键)之间的关联;
图11表示BPS纯品中氢质子与氢质子之间的关联;
图12表示BPS纯品中从质子到直接连接到碳以及同一质子自旋系统中的质子碳的碳维度的关联;
图13为BPS纯品与SARS-CoV-2RBD蛋白自组装电镜图谱;标尺为 500nm;
图14为BPS与SARS-CoV-2RBD蛋白形成的纳米疫苗的免疫调节活性结果。
具体实施方式
本发明提供了一种白及多糖,化学结构式如式I所示;所述白及多糖的相对分子量为42.0~42.5KDa;
在本发明中,所述白及多糖的相对分子量优选为42.4KDa。
在本发明中,所述白及多糖的单糖构成为甘露糖:葡萄糖=3.08:1;所述白及多糖的重复序列为1,4-β-D-葡萄糖(A)、1,4,6-β-D-甘露糖(C)和1,4-β-D- 甘露糖(B)按式I的重复单元为主链,单元(C)上乙酰基摩尔百分比含量为7.54%。
本发明还提供了上述方案所述白及多糖的制备方法,包括以下步骤:
1)对白及块茎粉进行脱脂处理,得到脱脂原料;
2)将所述脱脂原料和水混合进行水提,得到水提液;
3)采用乙醇对所述水提液进行醇沉,固液分离,收集沉淀;
4)对所述沉淀进行脱蛋白处理,得到白及粗多糖;
5)依次采用水和浓度为0.05mol/L的NaCl水溶液对所述白及粗多糖进行第一色谱柱层析,收集NaCl水溶液的洗脱部分;采用水对NaCl水溶液的洗脱部分进行第二色谱柱层析,收集洗脱液,对所述洗脱液进行HPLC-ELSD 检测,收集出峰时间为9.32min的组分,得到白及多糖。
本发明首先对白及块茎粉进行脱脂处理,得到脱脂原料。
在本发明中,所述白及块茎粉优选的采用白及块茎粉碎得到;本发明对所述白及块茎的粒径没有特殊限制,本领域常规粒径即可。
在本发明中,所述对白及块茎粉进行脱脂处理包括:将体积浓度为95%的乙醇水溶液和白及块茎粉混合后浸提,得到浸提液;对所述浸提液进行固液分离,收集沉淀,得到脱脂原料。
在本发明中,所述浸提的次数优选为3次;本发明对每次浸提采用的乙醇水溶液的用量没有特殊限制,以本领域常规用量即可。
在本发明中,对所述浸提液进行固液分离的方式优选为过滤;所述过滤采用的滤网的孔径优选为20~60目。
得到脱脂原料后,本发明将所述脱脂原料和水混合进行水提,得到水提液。在本发明中,所述水优选的包括去离子水;所述水提的方式优选的包括回流提取;所述回流提取的温度优选为80~100℃;所述回流提取的次数优选为3次,每次回流提取的时间优选为1~3h。
得到水提液后,本发明采用乙醇对所述水提液进行醇沉,固液分离,收集沉淀。在本发明中,采用乙醇对所述水提液进行醇沉的方法包括:对所述水提液进行过滤、浓缩,得到浓缩液;将所述浓缩液和乙醇混合,得到混合液,静置进行醇沉;所述混合液中乙醇的体积浓度优选的>70%。在本发明中,所述过滤采用的滤网的孔径优选为0.25~0.45;本发明对所述浓缩的方式没有特殊限制,采用本领域常规浓缩方式即可。在本发明具体实施过程中,所述浓缩的方式为减压浓缩。在本发明中,所述固液分离的方式优选为离心;所述离心的转速优选为3000~5000rpm;所述离心的时间优选为20~25min。
得到沉淀后,本发明对所述沉淀进行脱蛋白处理,得到白及粗多糖。在本发明的具体实施过程中,对所述沉淀进行脱蛋白处理的方法为:对所述沉淀复溶,得到复溶液;利用蛋白质在氯仿等有机溶剂中变性的特点,将复溶液与Sevage试剂按照体积比为4:1的比例混合、振荡、离心,变性后的蛋白质介于提取液与Sevage试剂交界处;所述Sevage试剂是将氯仿和正丁醇按照4:1的体积比混合得到。利用Sevage试剂去除所述上清液中的蛋白条件温和,不会引起多糖的变性。在本发明中,去除所述上清液中的蛋白的次数优选为3次。在本发明中,对所述沉淀复溶采用的试剂优选为水;所述水的温度优选为80~100℃。本发明对所述水的用量没有特殊限制,以使所述沉淀充分溶解即可。
得到白及粗多糖后,本发明依次采用水和浓度为0.05mol/L的NaCl水溶液对所述白及粗多糖进行第一色谱柱层析,收集NaCl水溶液的洗脱部分;采用水对NaCl水溶液的洗脱部分进行第二色谱柱层析,收集洗脱液,对所述洗脱液进行HPLC-ELSD检测,收集出峰时间为9.32min的组分,得到白及多糖。
在本发明中,所述第一色谱柱层析采用的色谱柱优选为DEAE-52色谱柱(80×4cm)。
在本发明中,所述第二色谱柱层析采用的色谱柱优选为浓度为 DEAE-SepharoseFast Flow、Sephadex G-75和Sephacryl S-200。在本发明具体实施过程中,0.05mol/L的NaCl水溶液的洗脱部分过DEAE-Sepharose Fast Flow、Sephadex G-75和Sephacryl S-200反复柱层析。
在本发明中,HPLC-ELSD检测的条件包括:色谱柱:TSKgel-G4000Wxl 7.8*30;流动相:水100%等度洗脱;时间:0~15min;进样量:10mL。
本发明还提供了上述方案所述白及多糖或上述方案所述制备方法制备得到的白及多糖在制备免疫调节产品中的应用。在本发明中,所述免疫调节产品优选的包括免疫调节药品、免疫调节化妆品或免疫调节功能食品。
本发明还提供了上述方案所述白及多糖或者上述方案所述制备方法制备得到的白及多糖作为免疫佐剂在制备疫苗中的应用。
本发明还提供了一种纳米疫苗,包括多糖和蛋白疫苗,所述多糖为上述方案所述白及多糖或者上述方案所述制备方法制备得到的白及多糖。在本发明中,所述多糖和蛋白疫苗的质量比优选为(4~50):(1~5),进一步优选为(10~30):(2~3)。
在本发明中,所述蛋白疫苗优选的包括SARS-CoV-2RBD蛋白。
本发明还提供了上述方案所述纳米疫苗的制备方法,包括以下步骤:
将所述白及多糖和蛋白疫苗混合,得到纳米疫苗。在本发明中,所述混合包括:将白及多糖和蛋白疫苗分别和水混合,分别得到白及多糖水溶液和蛋白疫苗水溶液;所述白及多糖水溶液中白及多糖的浓度优选为2~5mg/ml,更优选为3~4mg/ml;所述蛋白疫苗水溶液的浓度优选为1~5mg/ml,更优选为2~3mg/ml。在混合前,所述蛋白疫苗水溶液优选的经过0.25μm滤膜过滤处理;所述白及多糖水溶液和蛋白疫苗水溶液的体积比优选为(2~10): 1,进一步优选为(5~8):1。
在本发明中,所述混合的温度优选为20~30℃,更优选为25℃;本发明对所述混合的时间没有特殊限制,以混合均匀为准。
下面将结合本发明中的实施例,对本发明中的技术方案进行清楚、完整地描述。显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1:白及多糖提取分离纯化及结构鉴定
白及多糖提取的流程图参见图1。白及多糖分离纯化的流程参见图2。
1、取白及干燥粉末3kg,加入85%乙醇浸提三次,采用目径为00.25~0.45 目的滤纸过滤,滤渣置于室温通风晾干,然后沸水提取,加入20L蒸馏水,沸水提取2h,提取2次。
2、过滤,合并滤液,65℃减压浓缩至10L,向浓缩液中加入95%乙醇,慢加快搅,使醇终浓度达到70%,放置过夜,离心(5000rpm,20min),所得沉淀加10L的热水复溶,离心去除滤渣;
3、离心得到的上清液与Sevage试剂(氯仿和正丁醇按照4:1的体积比混合得到)按照体积比为4:1的比例混合、振荡、离心,变性后的蛋白质介于提取液与Sevage试剂交界处,重复两次步骤3,得到的剩余液浓缩,冷冻干燥,即得白及粗多糖BPS 250g。
4、每次取BPS 400mg,加3mL水,加热溶解,放至室温冷却,3000rpm 离心5min,得上清液,上清液用DEAE-52色谱柱(80×4cm),依次用蒸馏水、0.05、0.3和0.5mol/LNaCl水溶液为洗脱,自动接样器收集每一组分,用HPLC-ELSD检测合并相同出峰时间的组分,透析,每一组分减压浓缩到,后真空冷冻很干燥,得到3个组分BPS-0(水洗脱部分),BPS-1(0.05mol/LNaCl水溶液洗脱部分),BPS-2(0.3和0.5mol/LNaCl水溶液洗脱部分,含量少颜色深,因此没有继续纯化)。再进一步对BPS-0部分过DEAE-Sepharose Fast Flow再经和Sephacryl S-200反复柱层析,用水洗脱,自动接样器,每隔一管HPLC-ELSD检测合并得到BPS I。BPS-1部分过DEAE-Sepharose Fast Flow、Sephadex G-75和Sephacryl S-200反复柱层析,用水洗脱,自动接样器,每隔两管取样HPLC-ELSD检测(HPLC-ELSD检测的条件包括:色谱柱:TSKgel-G4000Wxl 7.8*30;流动相:水100%等度洗脱;时间:0~15min;进样量:10mL)合并分离纯化得到BPS II、BPS III和BPS IV。其中BPS II 为目标产物-具有免疫调节作用的白及多糖。
BPS纯品(BPS II)的HPLC图谱参见图3。采用多糖链接组成甲基化分析(PMP-HPLC);红外光谱分析;紫外和旋光分析及NMR光谱测定,最终确定均一多糖的结构为分子量≈42.4KDa,单糖构成为甘露糖:葡萄糖=3.08:1,多糖重复序列为1,4-β-D-葡萄糖(A)、1,4,6-β-D-甘露糖(C)和1,4-β-D- 甘露糖(B)按如下图的重复单元为主链,单元C上乙酰基含量为7.54%,结构如下:
多糖链接组成甲基化分析结果参见图4。
红外光谱分析(IR)结果参见图5。
紫外和旋光分析结果参见图6。
NMR光谱测定是确定BPS纯品的结构构成及单糖连接方式的重要手段,NMR光谱测定结果参见图7~图12,其中图7表示BPS纯品中所有的氢质子信号,图8表示BPS纯品中所有的氢原子信号,图9表示BPS纯品中碳与其附着氢质子之间的关联性,图10表示BPS纯品中氢质子与碳(包括非质子碳、远离质子的两个或三个键)之间的关联,该结构具有杂核多键相关性,图11表示BPS纯品中氢质子与氢质子之间的关联,图12表示BPS 纯品中从质子到直接连接到碳以及同一质子自旋系统中的质子碳的碳维度的关联。
实施例2:纳米疫苗的制备
取白及均一多糖10mg溶于2ml纯水配置成浓度为5mg/ml的多糖水溶液,过0.25μm滤膜过滤备用。取SARS-CoV-2RBD蛋白适量加纯水配制成浓度为3mg/ml蛋白疫苗水溶液,过0.25μm滤膜过滤备用。在纯水缓冲液中(pH 7.0),利用上述制备好的多糖水溶液与SARS-CoV-2RBD蛋白疫苗水溶液以5:1比例混匀,形成纳米疫苗,现配现用。
实施例3:纳米疫苗透射电镜
将上述实施例2中所制备的纳米疫苗,取10μL,利用透射电子显微镜 (TEM)观察纳米疫苗的形态。结果参见图13,由图13可以看出该均一多糖与疫苗自组装成均一圆形颗粒即纳米疫苗。
实施例4多糖BPS与SARS-CoV-2RBD蛋白形成的纳米疫苗的免疫调节活性
动物免疫的具体方法:将上述实施例2中所制备的纳米疫苗免疫动物,动物选用SPF级的BALB/c小鼠,6~8周龄,在无菌环境下饲养,分为3组,每组5只。具体的动物实验分组:
阴性对照组:肌肉注射生理盐水100μl/只鼠;
普通疫苗组:肌肉注射SARS-CoV-2RBD蛋白疫苗溶液10μg/只鼠;
纳米疫苗组:肌肉注射BPS-RBD纳米疫苗10μg/只鼠;
上述三组动物免疫时间间隔为0、2、4周,最后一次免疫后10天采血做假病毒中和实验与IFN-γELISPOT检测。检测结果参见表1、表2和图14,由表1、表2和图14可以看出组装后的纳米疫苗活性较普通疫苗有显著差异。
表1中和抗体检测结果
组别 | 中和抗体检测 |
阴性对照组 | 3.5 |
普通疫苗组 | 45.2 |
纳米疫苗组 | 279 |
表2IFN-γELISPOT实验结果
组别 | IFN-γELISPOT实验 |
阴性对照组 | 11 |
普通疫苗组 | 28 |
纳米疫苗组 | 86 |
所有动物实验经中国医学科学院医学生物学研究所动物实验伦理委员会批准,严格按照云南省实验室动物福利与伦理委员会规定操作。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
2.根据权利要求1所述的白及多糖,其特征在于,所述白及多糖的相对分子量为42.4KDa。
3.权利要求1或2所述白及多糖的制备方法,包括以下步骤:
1)对白及块茎粉进行脱脂处理,得到脱脂原料;
2)将所述脱脂原料和水混合进行水提,得到水提液;
3)采用乙醇对所述水提液进行醇沉,固液分离,收集沉淀;
4)对所述沉淀进行脱蛋白处理,得到白及粗多糖;
5)依次采用水和浓度为0.05mol/L的NaCl水溶液对所述白及粗多糖进行第一色谱柱层析,收集NaCl水溶液的洗脱部分;采用水对NaCl水溶液的洗脱部分进行第二色谱柱层析,收集洗脱液,对所述洗脱液进行HPLC-ELSD检测,收集出峰时间为9.32min的组分,得到白及多糖。
4.根据权利要求3所述的制备方法,其特征在于,步骤3)中所述采用乙醇对所述水提液进行醇沉包括:对所述水提液依次进行过滤和浓缩,得到浓缩液;将所述浓缩液和乙醇混合,得到混合液,静置进行醇沉;所述混合液中乙醇的体积浓度>70%。
5.根据权利要求3所述的制备方法,其特征在于,步骤4)中所述脱蛋白处理包括:对所述沉淀复溶,得到复溶液;将所述复溶液与Sevage试剂按照体积比为4:1的比例混合、振荡、离心,变性后的蛋白质介于复溶液与Sevage试剂交界处;所述Sevage试剂是将氯仿和正丁醇按照4:1的体积比混合得到。
6.权利要求1或2所述白及多糖或者权利要求3或4所述制备方法制备得到的白及多糖在制备免疫调节产品中的应用。
7.根据权利要求6所述的应用,其特征在于,所述免疫调节产品包括免疫调节药品、免疫调节化妆品或免疫调节功能食品。
8.权利要求1或2所述白及多糖或者权利要求3或4所述制备方法制备得到的白及多糖作为免疫佐剂在制备疫苗中的应用。
9.一种纳米疫苗,包括多糖和蛋白疫苗,所述多糖为权利要求1或2所述白及多糖或者权利要求3或4所述制备方法制备得到的白及多糖。
10.根据权利要求9所述纳米疫苗,其特征在于,所述蛋白疫苗包括SARS-CoV-2RBD蛋白。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110328789.3A CN115124628B (zh) | 2021-03-27 | 2021-03-27 | 一种白及多糖及其制备方法和应用、包含所述白及多糖的免疫佐剂和纳米疫苗 |
PCT/CN2021/093326 WO2022205572A1 (zh) | 2021-03-27 | 2021-05-12 | 一种白及多糖及其制备方法和应用、包含所述白及多糖的免疫佐剂和纳米疫苗 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110328789.3A CN115124628B (zh) | 2021-03-27 | 2021-03-27 | 一种白及多糖及其制备方法和应用、包含所述白及多糖的免疫佐剂和纳米疫苗 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115124628A true CN115124628A (zh) | 2022-09-30 |
CN115124628B CN115124628B (zh) | 2023-03-31 |
Family
ID=83374425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110328789.3A Active CN115124628B (zh) | 2021-03-27 | 2021-03-27 | 一种白及多糖及其制备方法和应用、包含所述白及多糖的免疫佐剂和纳米疫苗 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115124628B (zh) |
WO (1) | WO2022205572A1 (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861243A (en) * | 1989-10-14 | 1999-01-19 | Chemotherapeutisches Forschunginstitut Georg Speyer-Haus Zu Frankfurt A.M. | Vaccine for protection against HIV infections, process for preparing same and their use as diagnostic and agent immunotherapeutic agent |
CN101195839A (zh) * | 2007-12-28 | 2008-06-11 | 中华全国供销合作总社南京野生植物综合利用研究院 | 白芨多糖胶精制工艺 |
CN101518556A (zh) * | 2009-04-07 | 2009-09-02 | 浙江大学 | 具有抗肿瘤和免疫佐剂作用的多糖及其制备方法和用途 |
CN110184298A (zh) * | 2019-05-15 | 2019-08-30 | 武汉璟泓万方堂医药科技股份有限公司 | Hiv突变型表面糖蛋白及其纳米化抗原与制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100594939C (zh) * | 2008-04-25 | 2010-03-24 | 山东省眼科研究所 | 有协同治疗作用的眼用药物缓释载体 |
CN110684812A (zh) * | 2019-11-15 | 2020-01-14 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 一种具有免疫活性的白及多糖及其制备方法与应用 |
-
2021
- 2021-03-27 CN CN202110328789.3A patent/CN115124628B/zh active Active
- 2021-05-12 WO PCT/CN2021/093326 patent/WO2022205572A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861243A (en) * | 1989-10-14 | 1999-01-19 | Chemotherapeutisches Forschunginstitut Georg Speyer-Haus Zu Frankfurt A.M. | Vaccine for protection against HIV infections, process for preparing same and their use as diagnostic and agent immunotherapeutic agent |
CN101195839A (zh) * | 2007-12-28 | 2008-06-11 | 中华全国供销合作总社南京野生植物综合利用研究院 | 白芨多糖胶精制工艺 |
CN101518556A (zh) * | 2009-04-07 | 2009-09-02 | 浙江大学 | 具有抗肿瘤和免疫佐剂作用的多糖及其制备方法和用途 |
CN110184298A (zh) * | 2019-05-15 | 2019-08-30 | 武汉璟泓万方堂医药科技股份有限公司 | Hiv突变型表面糖蛋白及其纳米化抗原与制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN115124628B (zh) | 2023-03-31 |
WO2022205572A1 (zh) | 2022-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110128562B (zh) | 一种抗肿瘤补骨脂多糖及其提取分离方法和在制备抗肿瘤药物方面的应用 | |
WO2017005134A1 (zh) | 一种具有抗病毒和免疫活性的亚麻籽多糖的制备及其应用 | |
CN110540603B (zh) | 知母多糖及其制备方法、鉴定方法和应用 | |
CN115124628B (zh) | 一种白及多糖及其制备方法和应用、包含所述白及多糖的免疫佐剂和纳米疫苗 | |
WO2019184025A1 (zh) | 一种利用陈皮制备聚阿拉伯半乳糖醛酸的方法 | |
CN112679564A (zh) | 一种人参特有化合物精氨酸糖苷af的分离纯化新方法 | |
CN108409807B (zh) | 一种分离制备锦葵素-3-o-葡萄糖苷的方法 | |
CN114057907B (zh) | 一种红参多糖的提取和分离纯化方法 | |
CN113480674B (zh) | 一种黑茶多糖-ⅰ活性成分及其制备方法和在抗癌中应用 | |
CN113121716B (zh) | 一种促凝血紫荆花多糖及其提取分离方法和应用 | |
CN112898445B (zh) | 一种粗根荨麻多糖的分离提取方法及应用 | |
CN111320708B (zh) | 一种芦根多糖及其制备方法和用途 | |
CN110204627B (zh) | 一种美网柄牛肝菌多糖及其制备方法和应用 | |
CN108948223B (zh) | 桃金娘多糖p1及其分离方法和在制备降血脂药物中的应用 | |
WO2014173058A1 (zh) | 一种槐耳多糖蛋白及其制备方法和用途 | |
CN109206532B (zh) | 一种从桃金娘果实中提取并分离纯化多糖的方法 | |
CN112159484A (zh) | 一种抗凝血流苏子多糖及其提取分离方法和应用 | |
CN109678981B (zh) | 一种红花多糖的制备方法、产品及应用 | |
CN107936133B (zh) | 一种月见草叶多糖及其制备方法 | |
WO2014173059A1 (zh) | 一种槐耳多糖蛋白及其制备方法和用途 | |
CN111647095B (zh) | 一种白树多糖及其制备方法和应用 | |
CN111892662B (zh) | 垂盆草均一多糖及制备方法和用途 | |
WO2014173056A1 (zh) | 槐耳多糖蛋白及其制备方法和用途 | |
WO2014173057A1 (zh) | 一种槐耳多糖蛋白及其制备方法和用途 | |
CN116731222B (zh) | 荨麻鼠李半乳糖醛酸聚糖及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |